SubsidieMeestersDisruptive, drug free treatment of knee osteoarthritis using novel materials and minimally invasive catheter delivery
EmboSure is a minimally invasive treatment for Knee Osteoarthritis that uses bioresorbable particles to block blood vessels, providing long-term pain relief and halting disease progression for up to 5 years.
Projectdetails
Introduction
EmboSure is a breakthrough treatment for Knee Osteoarthritis. It acts directly on the mechanism of Osteoarthritis, delivers long-term pain relief, and stops the progression of the disease for up to 5 years.
Mechanism of Action
The solution involves embolising or blocking the tiny blood vessels of the knee with patented bioresorbable particles developed by CrannMed.
Particle Characteristics
- The bioresorbable embolic particles are tightly calibrated 200µm particles.
- They are made from naturally occurring biocompatible materials.
- These particles block the small blood vessels of the knee over a five-day period.
Treatment Process
This process disrupts the osteoarthritic degradation before the particles are completely reabsorbed into the body.
Delivery Method
The particles are delivered through a minimally invasive microcatheter, specifically designed by CrannMed to reach the tortuous vessels of the knee.
Importance of Blood Supply
As the maintenance of blood supply to the knee and the lower leg is critical, the bioresorbable particles and microcatheter are key to our paradigm to treat without leaving anything behind.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.488.572 |
| Totale projectbegroting | € 3.555.104 |
Tijdlijn
| Startdatum | 1-5-2022 |
| Einddatum | 30-11-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- CRANNMED LTDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
First in class lateral meniscus prothesis to relieve pain and restore mobility for KOA patientsATRO Medical's Trammpolin is a minimally invasive knee prosthesis designed to relieve pain and restore mobility in severe KOA patients, aiming for market entry in 2026 with a focus on health economics for reimbursement. | EIC Accelerator | € 2.499.402 | 2023 | Details |
Articular Cartilage Treatment with Injectable hydrogel is Valuable and long-term EffectiveHy2Care develops a regenerative injectable hydrogel for cartilage repair, promoting natural healing and long-lasting joint health while preventing osteoarthritis. | EIC Accelerator | € 2.500.000 | 2022 | Details |
To deliver the first medical treatment dedicated to patients with haemorrhagic strokeNANOp2lysis develops O2L-001, a safe, effective thrombolytic agent for intracerebral hematoma treatment via a single injection, enhancing delivery and reducing side effects post-hemorrhagic stroke. | EIC Accelerator | € 2.500.000 | 2022 | Details |
A breakthrough active immunotherapy for the treatment of osteoarthritisPeptinov aims to halt osteoarthritis progression through a cost-effective immunotherapy that neutralizes IL-6, with promising Phase I results leading to a Phase II trial for out-licensing readiness. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Rebuilding Joint Surface to Prevent Pain and ImmobilityAskel's COPLA® implant promotes cartilage regeneration and quick rehabilitation to prevent osteoarthritis, aiming to establish a gold standard for pain-free joint movement and improved quality of life. | EIC Accelerator | € 2.499.000 | 2022 | Details |
First in class lateral meniscus prothesis to relieve pain and restore mobility for KOA patients
ATRO Medical's Trammpolin is a minimally invasive knee prosthesis designed to relieve pain and restore mobility in severe KOA patients, aiming for market entry in 2026 with a focus on health economics for reimbursement.
Articular Cartilage Treatment with Injectable hydrogel is Valuable and long-term Effective
Hy2Care develops a regenerative injectable hydrogel for cartilage repair, promoting natural healing and long-lasting joint health while preventing osteoarthritis.
To deliver the first medical treatment dedicated to patients with haemorrhagic stroke
NANOp2lysis develops O2L-001, a safe, effective thrombolytic agent for intracerebral hematoma treatment via a single injection, enhancing delivery and reducing side effects post-hemorrhagic stroke.
A breakthrough active immunotherapy for the treatment of osteoarthritis
Peptinov aims to halt osteoarthritis progression through a cost-effective immunotherapy that neutralizes IL-6, with promising Phase I results leading to a Phase II trial for out-licensing readiness.
Rebuilding Joint Surface to Prevent Pain and Immobility
Askel's COPLA® implant promotes cartilage regeneration and quick rehabilitation to prevent osteoarthritis, aiming to establish a gold standard for pain-free joint movement and improved quality of life.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
An injectable and programmable drug-eluting embolic deviceThis project develops a novel biodegradable drug delivery platform for liver cancer treatment, utilizing a two-step method to enhance drug perfusion and reduce adverse effects before vessel blockage. | ERC Proof of... | € 150.000 | 2023 | Details |
Development of a Complete Triple Action Injectable Treatment for OsteoarthritisRelevium Ltd aims to validate and commercialize Hydrobloc, a unique therapy that regenerates cartilage, alleviates pain, and improves joint function in osteoarthritis patients. | EIC Transition | € 2.398.115 | 2022 | Details |
Disruptive Therapies for the long-term relief of Osteoarthritis PainThe Arth-Alleve project aims to develop a non-pharmaceutical, long-term therapy using neurotoxin-loaded hydrogels to effectively manage chronic pain in osteoarthritis patients, improving their quality of life. | ERC Consolid... | € 1.998.885 | 2023 | Details |
Occlufibre haalbaarheidOcclufibre onderzoekt de ontwikkeling van een op maat gemaakte embolisatie fibre voor veiligere en snellere interventies bij vaatafwijkingen. | Mkb-innovati... | € 20.000 | 2024 | Details |
SyCap MechanoAvalanche Medical ontwikkelt een duurzaam kunststof implantaat voor kraakbeendefecten in de knie, gericht op middelbare leeftijd patiënten. | Mkb-innovati... | € 20.000 | 2022 | Details |
An injectable and programmable drug-eluting embolic device
This project develops a novel biodegradable drug delivery platform for liver cancer treatment, utilizing a two-step method to enhance drug perfusion and reduce adverse effects before vessel blockage.
Development of a Complete Triple Action Injectable Treatment for Osteoarthritis
Relevium Ltd aims to validate and commercialize Hydrobloc, a unique therapy that regenerates cartilage, alleviates pain, and improves joint function in osteoarthritis patients.
Disruptive Therapies for the long-term relief of Osteoarthritis Pain
The Arth-Alleve project aims to develop a non-pharmaceutical, long-term therapy using neurotoxin-loaded hydrogels to effectively manage chronic pain in osteoarthritis patients, improving their quality of life.
Occlufibre haalbaarheid
Occlufibre onderzoekt de ontwikkeling van een op maat gemaakte embolisatie fibre voor veiligere en snellere interventies bij vaatafwijkingen.
SyCap Mechano
Avalanche Medical ontwikkelt een duurzaam kunststof implantaat voor kraakbeendefecten in de knie, gericht op middelbare leeftijd patiënten.